ODAC heeds Pazdur, recommends pulling Keytruda as third-line gastric cancer therapy
In hepatocellular carcinoma, ODAC votes favor Keytruda but not Opdivo
In hepatocellular carcinoma, ODAC votes favor Keytruda but not Opdivo.
FDA’s Oncologic Drugs Advisory Committee Thursday voted 6 to 2 to recommend withdrawal of accelerated approval for Merck’s Keytruda as third-line treatment of recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1.
The panel also voted on whether to retain accelerated approval for Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) and Opdivo nivolumab from Bristol Myers Squibb Co. (NYSE:BMY) for second-line hepatocellular